Vivasure Medical to exhibit at TCT 2017
Galway, Ireland – October 20, 2017 – Vivasure Medical is pleased to announce that it will exhibit its PerQseal® vascular technology at TCT 2017, which will take place at Colorado Convention Center in Denver CO, from October 29th – November 2nd. Vivasure will be at booth 4134 on the main exhibition floor.
Michael Laule, MD from the Charité Hospital in Berlin Germany, will present an interactive poster on Vivasure’s clinical results at the Large Bore Vascular Access and Closure session on Monday, October 30th at 2:24pm in the Exhibit Hall on the Exhibit Level.
Jeffrey J.Popma, MD from the Beth Israel Deaconess Medical Center in Boston, MA will present the PerQseal® technology during a session entitled Transcatheter Aortic Valve Therapies – Part 2, New Technologies Forum, on Tuesday, 31st October at 5:21pm in the Mile High Ballroom 2B/3B.
PerQseal® utilises a fully absorbable, intravascular patch, which seals large arteriotomies from the inside. It is comprised of a synthetic polymer implant, and an easy-to-use, ergonomically designed delivery system. After deployment, the implant is rapidly endothelialised and fully absorbed.
About Vivasure Medical
Based at one of Europe’s largest medtech hubs in Galway Ireland, Vivasure is focused on the development of absorbable implant technologies with vascular applications. Vivasure operates a fully integrated R&D and ISO 13485 certified manufacturing facility and is backed by leading international medtech investors.
Based on its patented PerQseal® technology, Vivasure has developed the world’s first fully absorbable, patch-based large-bore percutaneous closure devices. These new devices enable safe and reliable closure of large areriotomies in transcatheter procedures such as those used for Transcatheter Aortic Valve Replacement (TAVR) and Endovascular Anuerysm Repair (EVAR).